Search

Your search keyword '"Coluzzi, Sabrina"' showing total 15 results
Start Over Author "Coluzzi, Sabrina"
15 results on '"Coluzzi, Sabrina"'

1. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients

Author

Pascale, Sara Pasquina, primary, Nuccorini, Roberta, additional, Pierri, Teresa, additional, Di Mare, Roberta, additional, Fabio, Lucia, additional, Lerose, Emilia, additional, Merlino, Maria Antonietta, additional, Schiavo, Pietro, additional, Amendola, Angela, additional, Brucoli, Gino, additional, Caputo, Maria Denise, additional, Chitarrelli, Ida, additional, Cimminiello, Michele, additional, Coluzzi, Sabrina, additional, Filardi, Nunzio Biagio, additional, Matturro, Angela, additional, Vertone, Domenico, additional, Poggiaspalla, Monica, additional, Malaspina, Francesco, additional, Musuraca, Gerardo, additional, Coralluzzo, Gennaro, additional, Mannarella, Clara, additional, Musto, Clelia, additional, Bellettieri, Angela Pia, additional, Martinelli, Giovanni, additional, Cerchione, Claudio, additional, and Pizzuti, Michele, additional

Published
2022
Full Text
View/download PDF

2. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD

Author

Olivieri, Attilio, Cimminiello, Michele, Corradini, Paolo, Mordini, Nicola, Fedele, Roberta, Selleri, Carmine, Onida, Francesco, Patriarca, Francesca, Pavone, Enzo, Svegliati, Silvia, Gabrielli, Armando, Bresciani, Paola, Nuccorini, Roberta, Pascale, Sara, Coluzzi, Sabrina, Pane, Fabrizio, Poloni, Antonella, Olivieri, Jacopo, Leoni, Pietro, and Bacigalupo, Andrea

Published
2013
Full Text
View/download PDF

3. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Author

Soverini, Simona, primary, Bavaro, Luana, primary, De Benedittis, Caterina, primary, Martelli, Margherita, primary, Iurlo, Alessandra, primary, Orofino, Nicola, primary, Sica, Simona, primary, Sorà, Federica, primary, Lunghi, Francesca, primary, Ciceri, Fabio, primary, Galimberti, Sara, primary, Baratè, Claudia, primary, Bonifacio, Massimiliano, primary, Scaffidi, Luigi, primary, Castagnetti, Fausto, primary, Gugliotta, Gabriele, primary, Albano, Francesco, primary, Russo Rossi, Antonella Vita, primary, Stagno, Fabio, primary, di Raimondo, Francesco, primary, D’Adda, Mariella, primary, di Bona, Eros, primary, Abruzzese, Elisabetta, primary, Binotto, Gianni, primary, Sancetta, Rosaria, primary, Salvucci, Marzia, primary, Capodanno, Isabella, primary, Girasoli, Mariella, primary, Coluzzi, Sabrina, primary, Attolico, Immacolata, primary, Musolino, Caterina, primary, Calistri, Elisabetta, primary, Annunziata, Mario, primary, Bocchia, Monica, primary, Stella, Stefania, primary, Serra, Anna, primary, Errichiello, Santa, primary, Saglio, Giuseppe, primary, Pane, Fabrizio, primary, Vigneri, Paolo, primary, Mignone, Flavio, primary, Laginestra, Maria Antonella, primary, Pileri, Stefano Aldo, primary, Percesepe, Antonio, primary, Tenti, Elena, primary, Rosti, Gianantonio, primary, Baccarani, Michele, primary, Cavo, Michele, primary, and Martinelli, Giovanni, primary

Published
2020
Full Text
View/download PDF

6. Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

Author

Olivieri, Jacopo, Coluzzi, Sabrina, Attolico, Imma, and Olivieri, Attilio

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Chronic Graft Versus Host Disease (cGVHD) is a major complication of allogeneic stem-cell transplantation (SCT). In many inflammatory fibrotic diseases, such as Systemic Scleroderma (SSc) and cGVHD with fibrotic features, an abnormal activation of transforming growth factor (TGFβ) and platelet-derived growth factor receptor (PDGF-R) pathways have been observed. Tyrosin Kinase Inhibitors (TKIs), which are currently used for treatment of patients with Chronic Myeloid Leukemia (CML), share potent antifibrotic and antiinflammatory properties, being powerful dual inhibitors of both PDGF-R and TGFβ pathways. Moreover accumulating in vitro data confirm that TKIs, interacting with the TCR and other signalling molecules, carry potent immunomodulatory effects, being involved in both T-cell and B-cell response. Translation to the clinical setting revealed that treatment with Imatinib can achieve encouraging responses in patients with autoimmune diseases and steroid-refractory cGVHD, showing a favourable toxicity profile. While the exact mechanisms leading to such efficacy are still under investigation, use of TKIs in the context of clinical trials should be promoted, aiming to evaluate the biological changes induced in vivo by TKIs and to assess the long term outcome of these patients. Second-generation TKIs, with more favourable toxicity profile are under evaluation in the same setting.

Published
2011
Full Text
View/download PDF

7. What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Author

Soverini, Simona, Bavaro, Luana, De Benedittis, Caterina, Martelli, Margherita, Stella, Stefania, Vigneri, Paolo, Iurlo, Alessandra, Orofino, Nicola, Sica, Simona, Sorà, Federica, Galimberti, Sara, Baratè, Claudia, Albano, Francesco, Russo Rossi, Antonella, Ciceri, Fabio, Lunghi, Francesca, Castagnetti, Fausto, Gugliotta, Gabriele, Rosti, Gianantonio, Tenti, Elena, Stagno, Fabio, Novella, Elisabetta, Di Bona, Eros, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Salvucci, Marzia, D'Adda, Mariella, Sancetta, Rosaria, Calistri, Elisabetta, Bocchia, Monica, Capodanno, Isabella, Spinosa, Giuseppina, Laginestra, Maria Antonella, Errichiello, Santa, Serra, Anna, Carnuccio, Francesca, Coluzzi, Sabrina, Annunziata, Mario, Musolino, Caterina, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Cavo, Michele, and Martinelli, Giovanni

Published
2017
Full Text
View/download PDF

8. Association Between Immunoparesis and a Skewed Free Light Chain (FLC) Ratio: A New Prognostic Factor Of Progression from MGUS To Multiple Myeloma?

Author

Pizzuti, Michele, primary, Santagostino, Alberto, additional, Smaldore, Giuseppina, additional, Chitarrelli, Ida, additional, Vertone, Domenico, additional, Pascale, Sara Pasquina, additional, Matturro, Angela, additional, Attolico, Immacolata, additional, Amendola, Angela, additional, Cimminiello, Michele, additional, Filardi, Nunzio, additional, Girardi, Antonella, additional, Penitente, Romina, additional, Nuccorini, Roberta, additional, Coluzzi, Sabrina, additional, and Scavone, Enza, additional

Published
2013
Full Text
View/download PDF

9. Evaluation Of Factor V Leiden, Prothrombin Mutations and The Homozygous mutation 677T In The MTHFR Gene In Patients With Venous Thrombosis

Author

Pizzuti, Michele, primary, Santagostino, Alberto, additional, Rizzo, Maria Antonietta, additional, Dragonetti, Daniela, additional, Pietrafesa, Maria Grazia, additional, Attolico, Immacolata, additional, Amendola, Angela, additional, Filardi, Nunzio, additional, Cimminiello, Michele, additional, Matturro, Angela, additional, Vertone, Domenico, additional, Nuccorini, Roberta, additional, Pascale, sara Pasquina, additional, and Coluzzi, Sabrina, additional

Published
2013
Full Text
View/download PDF

10. Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning

Author

Attolico, Immacolata, primary, Nuccorini, Roberta, additional, Fragasso, Alberto, additional, Pavone, Vincenzo, additional, Musto, Pellegrino, additional, Capalbo, Silvana, additional, Palumbo, Gaetano, additional, Specchia, Giorgina, additional, Carniti, Cristiana, additional, Corradini, Paolo, additional, Pascale, Sara, additional, Coluzzi, Sabrina, additional, Pizzuti, Michele, additional, Amendola, Angela, additional, Cimminiello, Michele, additional, Matturro, Angela, additional, Vertone, Domenico, additional, Filardi, Nunzio, additional, and Olivieri, Attilio, additional

Published
2012
Full Text
View/download PDF

14. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study

Author

Anna Serra, Antonio Percesepe, Gabriele Gugliotta, Caterina Musolino, Gianni Binotto, Elisabetta Abruzzese, Immacolata Attolico, Gianantonio Rosti, Mario Annunziata, Rosaria Sancetta, Mariella Girasoli, Fabrizio Pane, Maria Antonella Laginestra, Sara Galimberti, Alessandra Iurlo, Stefania Stella, Sabrina Coluzzi, Simona Sica, Monica Bocchia, Marzia Salvucci, Francesca Lunghi, Fabio Stagno, Nicola Orofino, Stefano Pileri, Federica Sorà, Santa Errichiello, Elisabetta Calistri, Paolo Vigneri, Fausto Castagnetti, Michele Baccarani, Luana Bavaro, Michele Cavo, Eros Di Bona, Francesco Di Raimondo, Claudia Baratè, Margherita Martelli, Simona Soverini, Antonella Russo Rossi, Francesco Albano, Mariella D'Adda, Fabio Ciceri, Flavio Mignone, Elena Tenti, Caterina De Benedittis, Giuseppe Saglio, Isabella Capodanno, Giovanni Martinelli, Massimiliano Bonifacio, Luigi Scaffidi, Soverini, S., Bavaro, L., de Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sora, F., Lunghi, F., Ciceri, F., Galimberti, S., Barate, C., Bonifacio, M., Scaffidi, L., Castagnetti, F., Gugliotta, G., Albano, F., Rossi, A. V. R., Stagno, F., di Raimondo, F., D'Adda, M., di Bona, E., Abruzzese, E., Binotto, G., Sancetta, R., Salvucci, M., Capodanno, I., Girasoli, M., Coluzzi, S., Attolico, I., Musolino, C., Calistri, E., Annunziata, M., Bocchia, M., Stella, S., Serra, A., Errichiello, S., Saglio, G., Pane, F., Vigneri, P., Mignone, F., Laginestra, M. A., Pileri, S. A., Percesepe, A., Tenti, E., Rosti, G., Baccarani, M., Cavo, M., Martinelli, G., Soverini, Simona, Bavaro, Luana, De Benedittis, Caterina, Martelli, Margherita, Iurlo, Alessandra, Orofino, Nicola, Sica, Simona, Sora, Federica, Lunghi, Francesca, Ciceri, Fabio, Galimberti, Sara, Baratè, Claudia, Bonifacio, Massimiliano, Scaffidi, Luigi, Castagnetti, Fausto, Gugliotta, Gabriele, Albano, Francesco, Russo Rossi, Antonella Vita, Stagno, Fabio, Di Raimondo, Francesco, D'Adda, Mariella, Di Bona, Ero, Abruzzese, Elisabetta, Binotto, Gianni, Sancetta, Rosaria, Salvucci, Marzia, Capodanno, Isabella, Girasoli, Mariella, Coluzzi, Sabrina, Attolico, Immacolata, Musolino, Caterina, Calistri, Elisabetta, Annunziata, Mario, Bocchia, Monica, Stella, Stefania, Serra, Anna, Errichiello, Santa, Saglio, Giuseppe, Pane, Fabrizio, Vigneri, Paolo G, Mignone, Flavio, Laginestra, Maria Antonella, Pileri, Stefano A, Percesepe, Antonio, Tenti, Elena, Rosti, Gianantonio, Baccarani, Michele, Cavo, Michele, and Martinelli, Giovanni

Subjects
Oncology, Male, Mutation rate, bcr-abl, Drug Resistance, Fusion Proteins, bcr-abl, Gene mutation, medicine.disease_cause, Settore MED/01 - STATISTICA MEDICA, Biochemistry, Adult, Aged, Aged, 80 and over, Drug Resistance, Neoplasm, Female, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Middle Aged, Mutation, Mutation Rate, Prospective Studies, Protein Kinase Inhibitors, hemic and lymphatic diseases, 80 and over, cml mutation, BCR-ABL mutations, Chronic, Prospective cohort study, Sanger sequencing, Leukemia, Chronic myeloid leukemia, Myeloid leukemia, Hematology, TKI, NGS, symbols, Human, medicine.medical_specialty, Immunology, symbols.namesake, CML, TKIs, BCR-ABL1, Chronic myeloid leukemia,TKI,BCR-ABL mutations,Sanger Sequencing,NGS, Internal medicine, medicine, business.industry, Fusion Proteins, Cell Biology, medicine.disease, Clinical trial, Prospective Studie, Sanger Sequencing, Neoplasm, BCR-ABL Positive, business, Myelogenous
Abstract

In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is considered the gold standard for BCR-ABL1 KD mutation screening, next-generation sequencing (NGS) has recently been assessed in retrospective studies. We conducted a prospective, multicenter study (NEXT-in-CML) to assess the frequency and clinical relevance of low-level mutations and the feasibility, cost, and turnaround times of NGS-based BCR-ABL1 mutation screening in a routine setting. A series of 236 consecutive CML patients with failure (n = 124) or warning (n = 112) response to TKI therapy were analyzed in parallel by SS and NGS in 1 of 4 reference laboratories. Fifty-one patients (22 failure, 29 warning) who were negative for mutations by SS had low-level mutations detectable by NGS. Moreover, 29 (27 failure, 2 warning) of 60 patients who were positive for mutations by SS showed additional low-level mutations. Thus, mutations undetectable by SS were identified in 80 out of 236 patients (34%), of whom 42 (18% of the total) had low-level mutations somehow relevant for clinical decision making. Prospective monitoring of mutation kinetics demonstrated that TKI-resistant low-level mutations are invariably selected if the patients are not switched to another TKI or if they are switched to a inappropriate TKI or TKI dose. The NEXT-in-CML study provides for the first time robust demonstration of the clinical relevance of low-level mutations, supporting the incorporation of NGS-based BCR-ABL1 KD mutation screening results in the clinical decision algorithms.

Published
2020

15. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Author

Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, and Santoro M

Subjects
Carcinoma, Medullary pathology, Cell Line, Tumor, Cell Proliferation drug effects, ErbB Receptors antagonists & inhibitors, ErbB Receptors physiology, Humans, Mutation, Proto-Oncogene Proteins c-ret genetics, Proto-Oncogene Proteins c-ret physiology, Signal Transduction drug effects, Thyroid Neoplasms pathology, Transforming Growth Factor alpha pharmacology, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors, Carcinoma, Medullary drug therapy, Piperidines pharmacology, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-ret antagonists & inhibitors, Quinazolines pharmacology, Thyroid Neoplasms drug therapy
Abstract

Oncogenic conversion of the RET tyrosine kinase is a frequent feature of medullary thyroid carcinoma (MTC). ZD6474 (vandetanib) is an ATP-competitive inhibitor of RET, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptors kinases. In this study, we have studied ZD6474 mechanism of action in TT and MZ-CRC-1 human MTC cell lines, carrying cysteine 634 to tryptophan (C634W) and methionine 918 to threonine (M918T) RET mutation respectively. ZD6474 blunted MTC cell proliferation and RET, Shc and p44/p42 mitogen-activated protein kinase (MAPK) phosphorylation. Single receptor knockdown by RNA interference showed that MTC cells depended on RET for proliferation. Adoptive expression of the ZD6474-resistant V804M RET mutant rescued proliferation of TT cells under ZD6474 treatment, showing that RET is a key ZD6474 target in these MTC cells. Upon RET inhibition, adoptive stimulation of EGFR partially rescued TT cell proliferation, MAPK signaling, and expression of cell-cycle-related genes. This suggests that simultaneous inhibition of RET and EGFR by ZD6474 may overcome the risk of MTC cells to escape from RET blockade through compensatory over-activation of EGFR.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results